C9orf72 and amyotrophic lateral sclerosis: Although a 48% reduction in CSF polyGP was observed, this was not associated with stabilisation or improvement in functional outcomes compared to placebo (https://www.globenewswire.com/news-release/2023/05/23/2674200/0/en/Wave-Life-Sciences-Announces-Topline-Results-from-Phase-1b-2a-FOCUS-C9-Study-of-WVE-004-for-C9orf72-associated-Amyotrophic-Lateral-Sclerosis-and-Frontotemporal-Dementia.html, accessed on 25 April 2024).